200 1, the bioactive peptide raw material (intermediate) independently developed is listed as a major provincial project. In the same year, Shenzhen Hanyu Pharmaceutical Co., Ltd. was established with the approval of the US Food and Drug Administration.
In 2002, the polypeptide drug production base was listed as "Shenzhen High-tech Industrialization Demonstration Project" and was approved by the Shenzhen Municipal Government to build a polypeptide drug production base in Shenzhen High-tech Zone. At the same time, it is listed as a major construction project in Shenzhen; Polypeptide product research and development center is listed as Shenzhen engineering technology research and development center; And undertook the national "863" plan project and the national "Tenth Five-Year Plan" major scientific and technological projects.
In 2003, the polypeptide drug production base successfully passed the acceptance of national and provincial drug supervision departments, and obtained the Drug Production License and the Drug GMP Certificate. At the same time, it has undertaken key breakthrough award-winning projects in key areas of Guangdong Province.
In 2004, the polypeptide drug production base was listed as "national high-tech industrialization demonstration project"; Some polypeptide drugs have entered mass production and sales.
In 2005, the national "863" project and the national "Tenth Five-Year Plan" major scientific and technological projects undertaken by the company successfully passed the acceptance of the Ministry of Science and Technology; Polypeptide R&D Center is listed as Guangdong Engineering Technology R&D Center.
In 2006, the national high-tech new polypeptide drug industrialization demonstration project undertaken by the company successfully passed the acceptance of the National Development and Reform Commission.
In 2007, the export base of polypeptide drugs was listed as "national high-tech industrialization demonstration project"; Successfully passed the inspection of "the third national on-site meeting on special rectification of product quality and food safety"; To undertake the national "Eleventh Five-Year Plan" major science and technology projects; In 2007, Hanyu Pharmaceutical was selected as one of the "Top 0/00 Most Growing Technology Enterprises in China". Won the titles of "Shenzhen Science and Technology Innovation Award" and "Shenzhen Independent Innovation Industry Leading Enterprise".
In 2008, Hanyu Pharmaceutical strategically cooperated with Softbank Safran Asia Investment Fund and Shenzhen Innovation Investment Group to invest in Hanyu Pharmaceutical Phase I with a capital of150,000 USD. Guangdong Polypeptide Pharmaceutical Engineering Technology Research and Development Center passed the acceptance test successfully; The company was selected as "Top 50 High-tech and High-growth Enterprises in China in 2008".
On June 28, 2009, the company officially changed its name to "Shenzhen Hanyu Pharmaceutical Co., Ltd." and was recognized as "national high-tech enterprise"; Undertake and participate in three major scientific and technological projects of "National Major New Drug Creation" and two national high-tech industrialization projects; Won the second prize of Guangdong Science and Technology.
20 10 was awarded the title of "National High-tech Polypeptide Drug Industrialization Demonstration Project" by the National Development and Reform Commission; Selected in Forbes magazine "20 10 Top 200 Potential Enterprises in China"; Selected as "Deloitte Asia Pacific Top 500 High Growth"; Successfully completed the shareholding system reform and entered the approval stage of listing on the Growth Enterprise Market.
On 20 1 1 year, with the approval of China Securities Regulatory Commission, Hanyu Pharmaceutical made its initial public offering and listed on the Growth Enterprise Market, becoming the first synthetic peptide. Awarded "20 1 1 Guangdong Top 500 Enterprises"; R&D Center was recognized as "National Local Joint Engineering Laboratory" by the National Development and Reform Commission.
20 12 was selected as "20 12 Forbes China Most Potential Enterprise List".
20 13 was selected as "20 13 Forbes China Most Potential Enterprise List".